Vaccination Response Following Administration of Ixekizumab to Healthy Subjects

Trial Profile

Vaccination Response Following Administration of Ixekizumab to Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs Ixekizumab (Primary) ; DTaP vaccine; Pneumococcal vaccine
  • Indications Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 07 Nov 2017 Primary endpoint (Percentage of Participants with an Immune Response to Tetanus and Pneumococcal Vaccinations) has been met, according to the results published in the BioDrugs
    • 07 Nov 2017 Results published in the BioDrugs
    • 17 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top